Natera (NASDAQ:NTRA) Insider Sells 1,010 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,010 shares of the stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $260.49, for a total transaction of $263,094.90. Following the completion of the transaction, the insider owned 133,633 shares of the company’s stock, valued at $34,810,060.17. This trade represents a 0.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, July 28th, Solomon Moshkevich sold 1,204 shares of Natera stock. The stock was sold at an average price of $254.07, for a total value of $305,900.28.
• On Wednesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $272.90, for a total value of $818,700.00.
• On Monday, June 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $218.43, for a total value of $655,290.00.
• On Tuesday, May 26th, Solomon Moshkevich sold 1,652 shares of Natera stock. The shares were sold at an average price of $202.84, for a total value of $335,091.68.
• On Friday, May 1st, Solomon Moshkevich sold 3,405 shares of Natera stock. The stock was sold at an average price of $203.69, for a total value of $693,564.45.

Natera Price Performance

Shares of NTRA traded up $1.60 during midday trading on Wednesday, reaching $253.82. The stock had a trading volume of 925,147 shares, compared to its average volume of 1,091,572. The company has a market capitalization of $36.35 billion, a P/E ratio of -155.72 and a beta of 1.51. The firm’s 50 day moving average price is $244.16 and its 200-day moving average price is $221.65. Natera, Inc. has a 52 week low of $131.81 and a 52 week high of $288.04.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on NTRA. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a report on Friday, July 17th. Morgan Stanley lifted their price objective on shares of Natera from $250.00 to $310.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Sanford C. Bernstein initiated coverage on shares of Natera in a report on Friday, June 26th. They issued an “outperform” rating and a $310.00 target price on the stock. Piper Sandler reissued an “overweight” rating and set a $249.00 target price on shares of Natera in a research note on Tuesday, May 12th. Finally, Wall Street Zen lowered shares of Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $267.83.

Hedge Funds Weigh In On Natera

Institutional investors have recently bought and sold shares of the stock. Family Wealth Partners LLC purchased a new position in Natera in the 2nd quarter worth about $210,000. Handelsbanken Fonder AB boosted its holdings in shares of Natera by 29.1% in the second quarter. Handelsbanken Fonder AB now owns 207,800 shares of the medical research company’s stock worth $56,407,000 after buying an additional 46,800 shares during the period. Everhart Financial Group Inc. purchased a new position in shares of Natera in the second quarter worth approximately $254,000. Teamwork Financial Advisors LLC purchased a new position in shares of Natera in the second quarter worth approximately $2,936,000. Finally, FNY Investment Advisers LLC acquired a new stake in shares of Natera during the second quarter valued at approximately $59,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.